Merck: Keytruda gets mixed results in Phase III trial
(CercleFinance.com) - Just for once, Merck's blockbuster cancer drug has produced mixed results in a late-stage clinical trial, the company said late on Monday.
In its most recent Phase 3 trial, Merck's immunotherapy, in combination with chemotherapy, met one of its dual primary endpoints of progression-free survival in the first-line treatment of patients with extensive stage small cell lung cancer, a highly aggressive form of the disease.
While there was also an improvement in overall survival compared to chemotherapy alone, the trial did not meet statistical significance, Merck said.
Merck is currently continuing studies across multiple settings and stages of lung cancer, with over 10,000 patients enrolled.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
In its most recent Phase 3 trial, Merck's immunotherapy, in combination with chemotherapy, met one of its dual primary endpoints of progression-free survival in the first-line treatment of patients with extensive stage small cell lung cancer, a highly aggressive form of the disease.
While there was also an improvement in overall survival compared to chemotherapy alone, the trial did not meet statistical significance, Merck said.
Merck is currently continuing studies across multiple settings and stages of lung cancer, with over 10,000 patients enrolled.
Copyright (c) 2020 CercleFinance.com. All rights reserved.